v3.26.3
Restructuring Activities
12 Months Ended
Sep. 30, 2026
Restructuring and Related Activities [Abstract]  
Restructuring Activities

NOTE D – RESTRUCTURING ACTIVITIES

Restructuring activities

Ashland periodically implements restructuring programs related to acquisitions, divestitures and other cost reduction programs in order to enhance profitability through streamlined operations and an improved overall cost structure.

Restructuring programs

During the year ended September 30, 2025, Ashland initiated a restructuring plan to offset the impact from the Nutraceuticals business sale completed in fiscal 2024, the Avoca business sale completed in fiscal 2025, and other portfolio optimization actions ("2025 Restructuring Program"). As a part of the 2025 Restructuring Program, Ashland is also advancing a multi-year manufacturing network optimization to improve operational cost and strengthen its competitive position. The 2025 Restructuring Program continued into fiscal 2026.

During the year ended September 30, 2023, Ashland implemented targeted organizational restructuring actions to reduce costs ("2023 Restructuring Program"). The 2023 Restructuring Program is now completed.

Ashland recorded severance expense of $5 million, $13 million and $25 million during the years ended September 30, 2026, 2025 and 2024, respectively, within the selling, general and administrative expense caption of the Statements of Consolidated Comprehensive Income (Loss).

The following table details at September 30, 2026, the amount of restructuring severance liabilities related to these programs.

(In millions)

2025 Restructuring Program

 

 

2023 Restructuring Program

 

Balance at September 30, 2024

$

—

 

 

$

18

 

Restructuring expense (income)

 

14

 

 

 

(1

)

Utilization (cash paid)

 

(9

)

 

 

(16

)

Balance at September 30, 2025(a)

$

5

 

 

$

1

 

Restructuring expense

 

4

 

 

 

1

 

Utilization (cash paid)

 

(7

)

 

 

(2

)

Balance at September 30, 2026(a)

$

2

 

 

$

—

 

 

 

 

 

 

 

(a)
The restructuring severance liability associated with these programs is recorded within accrued expenses and other liabilities in the Consolidated Balance Sheets at September 30, 2026 and 2025.

Plant optimization actions

Ashland's portfolio optimization actions have included manufacturing network optimization projects associated with carboxymethylcellulose ("CMC"), industrial methylcellulose ("MC"), vinyl pyrrolidone and derivatives ("VP&D") and hydroxyethylcellulose ("HEC").

During the year ended September 30, 2026, Ashland incurred $4 million of accelerated depreciation for product line optimization activities associated with a Specialty Additives manufacturing facility, which was recorded within the cost of sales caption of the Statement of Consolidated Comprehensive Income (Loss).

During the year ended September 30, 2025, Ashland incurred $21 million, $1 million and $19 million of accelerated depreciation for product line optimization activities associated with manufacturing facilities within the Life Sciences, Personal Care and Specialty Additives reportable segments, respectively, which was recorded within the cost of sales caption of the Statement of Consolidated Comprehensive Income (Loss).

During the year ended September 30, 2024, Ashland incurred $55 million of accelerated depreciation for product line optimization activities associated with two Specialty Additives manufacturing facilities, which was recorded within the cost of sales caption of the Statement of Consolidated Comprehensive Income (Loss).

During the year ended September 30, 2024, Ashland incurred $2 million of accelerated depreciation for product line optimization activities associated with a Personal Care manufacturing facility in Summerville, South Carolina, which was recorded within the cost of sales caption of the Statement of Consolidated Comprehensive Income (Loss).